Total
0
Shares
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • eHealth software provider Respiri (RSH) has completed a share purchase plan (SPP) to raise $3.14 million
  • Originally, Respiri sought to raise $1 million, however, due to strong support the capacity was increased to $3.14 million
  • More than 57 million shares will be issued for 5.5 cents each
  • The SPP follows a private placement completed in March that raised $2 million, bringing the total capital raised in recent months to $5.1 million
  • Respiri says that it is now well capitalised for the commercial launch of its asthma management Wheezo device and platform planned for later this year
  • Company shares are down 1.43 per cent and trading for 6.9 cents each

eHealth software provider Respiri (RSH) has completed a share purchase plan (SPP) to raise $3.14 million.

Originally, Respiri sought to raise $1 million and had the capacity to accept subscriptions up to $2 million. However, due to strong support, the board increased the SPP capacity to raise up to $3.14 million.

This has now been completed and more than 57 million shares will be issued for 5.5 cents each.

The SPP follows a private placement in March that raised $2 million and brings the total capital raised in recent months to $5.1 million.

Respiri said that it is now well capitalised for the commercial launch of its asthma management Wheezo device and platform planned for later this year.

Specifically, when initially announcing the SPP, the company said that funds from the SPP and placement would be used for product and clinical development, manufacturing, sales and marketing of Wheezo.

Company shares are down 1.43 per cent and trading for 6.9 cents each at 2:27 pm AEST.

RSH by the numbers
More From The Market Herald
Zelira Therapeutics (ASX:ZLD) - CEO and MD, Dr Oludare Odumosu

" Zelira Therapeutics (ASX:ZLD) recieves funding from Quincy Street

Zelira Therapeutics (ZLD) has raised US$5 million (around A$6.69) from US family office fund, Quincy Street Capital.
Incannex Healthcare (ASX:IHL)

" Incannex Healthcare (ASX:IHL) engages Procaps to manufacture sleep apnoea treatment

Incannex Healthcare (IHL) has engaged a company to manufacture its soft-gel capsules in preparation for upcoming clinical trials.
(ASX:ATH) -

" Alterity Therapeutics (ASX:ATH) expands clinical development program

Alterity Therapeutics (ATH) is expanding the phase two clinical development program for its lead asset ATH434 in patients with Multiple System Atrophy (MSA).
Althea Group (ASX:AGH) - CEO, Joshua Fegan

" Althea Group (ASX:AGH) hits new high in sales receipts

Althea Group (AGH) brought in a new high of $4.5 million in customer receipts over the recently completed September quarter.